Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MASCT-I + apatinib
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cell Therapies, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
MASCT-I + apatinib is an investigational combination therapy involving Multi-Antigen Stimulated Cell Therapy-I (MASCT-I), an autologous adoptive cellular immunotherapy, and apatinib, an oral small-molecule VEGFR-2 tyrosine kinase inhibitor. MASCT-I involves dendritic cells (DCs) loaded with multiple tumor antigens and infused cytotoxic T lymphocytes (CTLs) activated by PD-1 blockade. Apatinib specifically inhibits VEGFR-2, suppressing tumor angiogenesis, and may also modulate tumor immune microenvironment, making it synergistic with immunotherapies. The combination has been studied for advanced solid tumors (notably sarcomas), showing promising responses and progression-free survival improvement without markedly increased toxicity.
- Other names
- Multi-Antigen Stimulated Cell Therapy-I plus apatinibMASCT-I plus apatinibMASCT-I combined with apatinibrivoceranib (for apatinib)
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)SRC (Proto-oncogene tyrosine-protein kinase Src)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on MASCT-I + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MASCT-I + apatinib.